文献速递血栓与止血

成人原发免疫性血小板减少症对糖皮质激素无效或依赖的治疗策略

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment.
PubMed 文献 · Blood · 2021-01-01

约80%的成人免疫性血小板减少症(ITP)患者对糖皮质激素治疗失败或依赖,需二线治疗。建议脾切除延迟至少12至24个月,优先选用有充分临床试验证据的TPO受体激动剂、利妥昔单抗和福坦替尼,并基于患者偏好个体化选择。

要点

  • 约80%成人ITP患者需二线治疗,脾切除应延迟至少12至24个月。
  • 优先选用有充分试验证据的药物:TPO受体激动剂、利妥昔单抗、福坦替尼。
  • TPO受体激动剂和福坦替尼为维持治疗,利妥昔单抗疗程有限但半数1-2年后失效。

核心结论

  • 对糖皮质激素无效或依赖的成人ITP患者,应延迟脾切除并优先选用有充分证据的药物治疗,实施个体化决策。

研究设计与样本

  • 本文为综述,基于文献总结成人原发ITP对糖皮质激素无效或依赖患者的治疗策略。

主要发现

  • 约80%的成人ITP患者对糖皮质激素治疗失败或依赖,需要二线治疗。
  • 脾切除应延迟至少12至24个月,以使更多患者通过药物治疗获得缓解。
  • 利妥昔单抗应答者中约半数在给药后1至2年失去应答,需再治疗或其他治疗。

关键数值与推荐

  • 推荐使用有丰富临床试验证据的药物,如TPO受体激动剂、利妥昔单抗和福坦替尼。
  • 脾切除应延迟至少12至24个月再考虑。
  • TPO受体激动剂和福坦替尼为维持治疗,利妥昔单抗为有限疗程给药。

临床怎么用

  • 治疗选择应结合药物疗效、安全性、作用机制和给药方式,并纳入患者偏好与价值观进行个体化决策。
  • 对糖皮质激素无效或依赖的成人ITP患者,优先选用有充分证据的药物治疗而非立即脾切除。

局限性

  • 目前没有可靠的生物标志物帮助选择治疗。
  • 各药物治疗方案在疗效、安全性和给药方式上存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 80% of adult patients with immune thrombocytopenia (ITP) have treatment failure with corticosteroids or become dependent on them and require second-line therapy. Several new and effective therapies have been introduced during the past decade and our understanding of disease burden and its effect on quality of life has expanded. It is now recommended that splenectomy, the standard second-line therapy for decades, be delayed for at least 12 to 24 months, allowing for more patients to achieve remission on medical therapies before considering surgery. It is highly recommended that medical therapies be used that have abundant clinical trial evidence, such as the thrombopoietin receptor agonists (TPO-RAs) rituximab and fostamatinib. Unfortunately, there are no reliable biomarkers that help in treatment selection. These therapeutic medical options have variable efficacy, safety profiles, mechanisms of action, and modes of administration. This enables and mandates an individualized approach to treatment, where patient involvement, preferences and values have become central to the process of choosing the appropriate therapy. Both TPO-RAs and fostamatinib are maintenance therapies, whereas rituximab is given for a limited number of doses. Although the response is usually maintained while receiving a TPO-RA or fostamatinib therapy, half of rituximab responders will no longer respond 1 to 2 years after administration and require retreatment or other therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ghanima W, Gernsheimer T, Kuter DJ, et al. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood. 2021. PMID: 33827138. doi:10.1182/blood.2021010968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。